Wearable activity signatures to spot risk of additional chronic conditions
Association of a Digital Signature of Physical Activity and Sedentary Lifestyle With the Development of Multimorbidities Over 4 Years of Follow-up in Chronic Diseases (eMOB) : a Prospective Cohort
This project tests whether wearable sensors can find activity patterns that predict new chronic conditions in people who already have chronic diseases.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 700 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Locations | 1 site (Clermont-Ferrand) |
| Trial ID | NCT05578495 on ClinicalTrials.gov |
What this trial studies
The eMOB study will follow 700 patients with a range of chronic diseases at CHU Clermont-Ferrand for four years, collecting annual clinical measures and continuous movement data from accelerometers and wearable sensors. Researchers will combine quantitative movement metrics with detailed sequence analysis and tailor algorithms to each disease and context to derive a personalized digital signature of physical activity and sedentary behavior. They will then examine whether that signature is associated with the later appearance of one or more additional comorbidities during follow-up. The approach aims to detect risk patterns before clinical complications arise so that earlier interventions might be possible.
Who should consider this trial
Good fit: Adults already followed in CHU Clermont-Ferrand observational cohorts for conditions such as rheumatoid arthritis, spondyloarthritis, pre‑surgical knee or hip osteoarthritis, major depressive or bipolar disorder, type 2 diabetes, obesity, COPD, or chronic pain who can wear an accelerometer and attend annual visits are ideal candidates.
Not a fit: People without chronic disease, those not followed at CHU Clermont-Ferrand, or those unable or unwilling to wear sensors or attend yearly follow-up visits are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this could help clinicians identify people at higher risk of new chronic conditions earlier and target interventions to prevent or delay complications.
How similar studies have performed: Previous work has linked accelerometer-measured activity to outcomes within individual diseases, but applying a cross-disease, personalized digital signature to predict new multimorbidities is relatively novel and not yet established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient follow-up at CHU Clermont-Ferrand for a chronic disease in one of the following observational cohorts: * Inflammatory rheumatic disease(rheumatoid arthritis, spondyloarthritis) included in the RCVRIC cohort (CPP Sud-Est VI N° ID-RCB- A01847-40) * Pre-surgical knee and hip osteoarthritis (Evalmob) (ID-RCB N° 2019- A01017-50) * Major depressive disorder included in the FACE-DR cohort (CNIL agreement: DR- 2015-673) and Bipolar disorder included in the FACE-BD cohort (CPP Ile de France IX; January 18, 2010) of the Adult Psychiatry Department B * Type 2 diabetes included in the cohort of the sport medicine service "Rehabilitation T2" (CNIL agreement 0164) * Obesity included in the "Obesity" sports medicine service cohort (CNIL agreement 0164) * COPD included in the "COPD Rehabilitation" sports medicine service cohort (CNIL agreement 0164) * Chronic pain cohort (eDOL) (CPP West II N° ID-RCB 2020-A02027-32) * Affiliation to a social security system. * Able to provide written informed consent to participate in the research. Exclusion Criteria: * Inability to practice physical activity * Pregnant or breastfeeding * Refusal to participate * Minors or adults under the protection of the law or under the protection of justice.
Where this trial is running
Clermont-Ferrand
- CHU de Clermont-Ferrand — Clermont-Ferrand, France (Recruiting)
Study contacts
- Principal investigator: Anne Tournadre — University Hospital, Clermont-Ferrand
- Study coordinator: Lise LACLAUTRE
- Email: promo_interne_drci@chu-clermontferrand.fr
- Phone: +33473754963
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.